相似文献
1
Platelet activating factor synthesis and metabolism in intestinal ischaemia-reperfusion injury.
Mediators Inflamm. 1994;3(5):393-5. doi: 10.1155/S0962935194000554.
2
Quantification of distinct molecular species of platelet activating factor in ulcerative colitis.
Lipids. 1996 Mar;31 Suppl:S255-9. doi: 10.1007/BF02637086.
3
Involvement of platelet-activating factor (PAF) in endotoxin- or ischaemia-induced intestinal hyperpermeability in the rat.
J Lipid Mediat. 1993 May;7(1):11-21.
4
Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury.
J Lipid Mediat. 1993 Aug;8(1):53-65.
5
Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig.
Br J Pharmacol. 1990 Nov;101(3):734-8. doi: 10.1111/j.1476-5381.1990.tb14149.x.
6
Early treatment with lexipafant, a platelet-activating factor-receptor antagonist, is not sufficient to prevent pulmonary endothelial damage after intestinal ischaemia and reperfusion in rats.
Dig Liver Dis. 2002 Mar;34(3):190-6. doi: 10.1016/s1590-8658(02)80192-x.
7
Renal allograft platelet activating factor synthesis during acute cellular rejection.
J Lipid Mediat. 1991 Jul-Aug;4(1):69-81.
8
Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts.
Cardiovasc Res. 1991 May;25(5):391-7. doi: 10.1093/cvr/25.5.391.
9
Quantification of distinct molecular species of the 2-lyso metabolite of platelet-activating factor by gas chromatography-negative-ion chemical ionization mass spectrometry.
J Chromatogr. 1992 Mar 27;575(2):183-96. doi: 10.1016/0378-4347(92)80145-g.
10
Study on the metabolism of lyso-platelet activating factor (lyso-PAF) in human paranasal sinus mucosa. The cultured ciliated epithelium can convert lyso-PAF to PAF.
Life Sci. 1993;52(21):PL227-32. doi: 10.1016/0024-3205(93)90483-j.
本文引用的文献
1
Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis.
Blood. 1993 Mar 1;81(5):1179-83.
2
Molecular regulation of B lymphocyte response.
Annu Rev Immunol. 1988;6:485-512. doi: 10.1146/annurev.iy.06.040188.002413.
3
Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells.
J Immunol. 1988 Sep 1;141(5):1529-35.
4
Regulation of human gamma-interferon and beta-interferon gene expression in PHA-activated lymphocytes.
J Interferon Res. 1986 Apr;6(2):161-70. doi: 10.1089/jir.1986.6.161.
5
IgG1 plasmacytosis in interleukin 6 transgenic mice.
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547-51. doi: 10.1073/pnas.86.19.7547.
6
The risk of neoplasms in patients treated with cyclosporine A.
J Autoimmun. 1989 Oct;2(5):723-31. doi: 10.1016/s0896-8411(89)80010-1.
7
A flow cytometric and immunofluorescence microscopic study of tumor necrosis factor production and localization in human monocytes.
Cell Immunol. 1989 Sep;122(2):405-15. doi: 10.1016/0008-8749(89)90087-7.
8
Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia.
Br J Haematol. 1989 Jun;72(2):278-84. doi: 10.1111/j.1365-2141.1989.tb07695.x.
9
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65. doi: 10.7164/antibiotics.40.1256.
10
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.
J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. doi: 10.7164/antibiotics.40.1249.
Zotero 插件